Online inquiry

IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9496MR)

This product GTTS-WQ9496MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9496MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9031MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ2545MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ3503MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ4641MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ1594MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ13715MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ15684MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ11891MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW